

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East),
Mumbai - 400 063, India

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited Review Report on unaudited consolidated financial results of Alkem Laboratories Limited for the quarter ended 31 December 2022 and year to date results for the period from 01 April 2022 to 31 December 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Alkem Laboratories Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alkem Laboratories Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2022 and year to date results for the period from 01 April 2022 to 31 December 2022 ("the Statement") which includes interim financial information of one branch, being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Registered Office

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Limited Review Report (Continued)

Alkem Laboratories Limited

6. We did not review the interim financial results of 2 subsidiaries included in the Statement, whose interim financial results reflects total revenues (before consolidation adjustments) of Rs 2,675 million and Rs. 7,977 million, total net profit after tax (before consolidation adjustments) of Rs. 103 million and Rs. 547 million and total comprehensive income (before consolidation adjustments) of Rs. 102 million and Rs 536 million, for the quarter ended 31 December 2022 and for the period from 01 April 2022 to 31 December 2022 respectively, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Balajirao Pothana

Partner

Mumbai

10 February 2023

Membership No.: 122632

UDIN:23122632BGZF1300

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1.	Alkem Laboratories Limited	Parent
2.	S & B Holdings 8 V., Netherlands (S&B Holdings)	Wholly Owned Subsidiary
3.	ThePharmaNetwork, LLC, USA (TPN)	Wholly Owned Subsidiary
4.	Ascend Laboratories LLC, USA	Wholly Owned Subsidiary of TPN
5.	S & B Pharma LLC	Wholly owned Subsidiary of TPN
6.	Pharmacor Pty Limited, Australia	Wholly Owned Subsidiary
7.	Enzene Biosciences Ltd, India	Subsidiary
8.	Ascend Laboratories (PTY) Ltd, South Africa (formerly known as Alkem Laboratories (PTY) Ltd)	Wholly Owned Subsidiary
9.	Cachet Pharmaceuticals Pvt Ltd, India	Subsidiary
10.	Indchemie Health Specialities Pvt Ltd, India	Subsidiary
11.	Alkem Laboratories Corporation, Philippines	Wholly Owned Subsidiary
12.	Ascend GmbH, Germany	Wholly Owned Subsidiary
13.	Ascend Laboratories SDN BHD., Malaysia	Wholly Owned Subsidiary
14.	Ascend Laboratories SpA, Chile (Ascend Chile)	Wholly Owned Subsidiary

Limited Review Report (Continued)

Alkem Laboratories Limited

15.	Pharma Network SpA, Chile	Wholly Owned Subsidiary of Ascend Chile
16.	Ascend Laboratories S.A. DE C.V., Mexico	Wholly Owned Subsidiary of Ascend Chile
17.	Alkem Laboratories Korea Inc, Korea	Wholly Owned Subsidiary
18.	Pharmacor Ltd., Kenya	Wholly Owned Subsidiary
19.	The Pharma Network, LLP, Kazakhstan	Wholly Owned Subsidiary
20.	Ascend Laboratories (UK) Ltd., UK	Wholly Owned Subsidiary
21.	Ascend Laboratories Ltd., Canada	Wholly Owned Subsidiary
22.	Alkem Foundation, India	Wholly Owned Subsidiary
23.	Connect 2 Clinic Private Limited, India	Wholly Owned Subsidiary
24.	Ascend Laboratories SAS, Colombia	Wholly Owned Subsidiary
25.	S & B Pharma Inc., USA	Wholly Owned Subsidiary of TPN (upto 05 January 2022)
26.	Pharmacor Limited, New Zealand	Wholly Owned Subsidiary of Pharmacor Pty Limited, Australia
27.	Enzene Inc., USA	Wholly Owned Subsidiary of Enzene Biosciences Ltd, India

16.

ALKEM LABORATORIES LIMITED

CIN No.:L00305MH1973PLC174201

Regd. Office and Corporate Office: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400013, Maharashtra, India.

Tel No:91 22 3982 9999 Fax No: +91 22 2492 7190

Website : www.alkemlabs.com, Email Id : investors@alkem.com

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine months ended 31 December 2022


(₹ in Million except per share data)

	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2022 Unaudited	30.09.2022 Unaudited	31.12.2021 Unaudited	31.12.2022 Unaudited	31.12.2021 Unaudited	31.03.2022 Audited
1	Income						
	(a) Revenue from Operations	30,409.1	30,793.7	26,189.8	86,966.6	81,503.3	106,341.9
	(b) Other Income	453.3	506.7	535.2	1,474.1	1,421.3	1,626.5
	Total Income	30,862.4	31,300.4	26,725.0	88,440.7	82,924.6	107,968.4
2	Expenses						
	(a) Cost of materials consumed	7,783.7	8,155.2	7,809.1	22,863.0	23,248.9	32,260.6
	(b) Purchases of stock-in-trade	4,015.4	3,412.5	3,788.8	10,408.7	11,877.1	14,897.1
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	690.3	1,501.8	(1,631.1)	3,241.5	(3,636.6)	(5,354.8)
	(d) Employee benefits expense	5,253.7	5,708.5	4,709.0	16,283.7	14,972.2	19,627.1
	(e) Finance costs	270.5	248.5	105.7	784.0	354.0	523.7
	(f) Depreciation and amortisation expense	784.4	774.0	774.6	2,321.0	2,208.2	3,039.6
	(g) Other expenses	6,675.5	7,476.6	6,529.5	21,607.7	17,884.8	24,382.7
	Total Expenses	25,473.5	27,277.1	22,085.6	77,509.6	66,908.6	89,376.0
3	Profit before exceptional items and tax (1) - (2)	5,388.9	4,023.3	4,639.4	10,931.1	16,016.0	18,592.4
4	Exceptional items (refer note 3)	-	-	-	-	-	(149.6)
5	Profit before tax (3) + (4)	5,388.9	4,023.3	4,639.4	10,931.1	16,016.0	18,442.8
6	Tax expense / (credit)						
	(a) Current tax	891.4	869.8	921.8	2,110.4	3,186.3	3,619.8
	(b) Deferred tax	(102.1)	(323.7)	(1,615.9)	(570.6)	(2,891.4)	(1,980.2)
	Total Tax Expense (a + b)	789.3	546.1	(694.1)	1,539.8	294.9	1,639.6
7	Profit for the period (5) - (6)	4,599.6	3,477.2	5,333.5	9,391.3	15,721.1	16,803.2
8	Other Comprehensive Income (net of tax)						
	(a) (i) Items that will not be reclassified to profit or loss	(7.8)	(25.4)	(14.6)	(34.9)	(72.9)	(90.9)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	2.6	8.9	4.5	11.8	26.5	33.2
	(b) (i) Items that will be reclassified to profit or loss	329.4	422.1	52.7	1,275.1	126.9	399.1
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income (net of tax)	324.2	405.6	42.6	1,252.0	80.5	341.4
9	Total Comprehensive Income for the period (7) + (8)	4,923.8	3,882.8	5,376.1	10,643.3	15,801.6	17,144.6
10	Profit attributable to						
	a) Owners of the Company	4,547.1	3,308.4	5,256.6	9,131.9	15,380.4	16,456.2
	b) Non-Controlling Interest	52.5	168.8	76.9	259.4	340.7	347.0
11	Other Comprehensive Income attributable to						
	a) Owners of the Company	324.8	411.6	41.7	1,257.0	87.5	345.5
	b) Non-Controlling Interest	(0.6)	(6.0)	0.9	(5.0)	(7.0)	(4.1)
12	Total Comprehensive Income attributable to						
	a) Owners of the Company	4,871.9	3,720.0	5,298.3	10,388.9	15,467.9	16,801.7
	b) Non-Controlling Interest	51.9	162.8	77.8	254.4	333.7	342.9
13	Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	239.1	239.1	239.1	239.1	239.1	239.1
14	Other Equity						86,139.9
15	Earnings Per Share (not annualised for the periods)						
	(a) Basic (₹)	38.03	27.67	43.96	76.38	128.64	137.63
	(b) Diluted (₹)	38.03	27.67	43.96	76.38	128.64	137.63

Notes to the Consolidated Financial results:

- 1 The above unaudited consolidated financial results of the Company were reviewed and recommended by the Audit Committee on 9 February 2023 and subsequently approved by the Board of Directors at its meeting held on 10 February 2023. The auditors have issued an unmodified report on the financial results for the quarter and nine months ended 31 December 2022.
- 2 The Company has entered into a Securities Subscription Agreement and Shareholders' Agreement dated 23 December 2022 with Enzene Biosciences Limited, a subsidiary of the Company ("Enzene"), Eight Roads Ventures India Healthcare IV, L.P. ("Eight Roads Ventures") and F-Prime Capital Partners Life Sciences Fund VI LP ("F-Prime Capital") towards subscription of Compulsorily Convertible Preference Shares ('CCPS') by Eight Roads Ventures and F-Prime Capital in Enzene for a consideration of Rs.1,614.8 million which is equivalent to 8% of the subsidiary's equity valuation.
- 3 During the previous year, the Group has fair valued one of its investments in the USA and considering the contingencies on business projections of the investee company an amount of Rs. 149.6 million has been debited to the Statement of Profit and Loss and disclosed as an exceptional item.
- 4 This being the 50th year of incorporation of the Company, the Board of Directors at its meeting held on 10 February 2023 have declared a Special Dividend of ₹ 25 (Rupees Twenty five only) per equity share. In addition to the Special Dividend, the Board have also declared an interim dividend of ₹ 15 (Rupees Fifteen only) per equity share amounting to a total interim dividend of ₹ 40 (Rupees Forty only) per equity share (2000% on the face value of ₹ 2 each) for the financial year ending 31 March 2023.
- 5 The Group operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.

By Order of the Board
For Alkem Laboratories Limited



B.N. Singh
Executive Chairman
DIN: 00760310

Place: Mumbai
Date: 10 February 2023